Consistent with the characteristics of memory T cells, we found that the effector and central memory PR1-CTL proliferated robustly, supporting our hypothesis that IFN treatment induces a self-renewing population of leukemia-specific CTL that may help to maintain anti-leukemia immunity and remission in the absence of ongoing treatment. The gene discussed is TMEM37; the disease is leukemia.